<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0//FR" "http://www.w3.org/TR/REC-html40/strict.dtd">
<!-- template_7 -->
<HTML>
  <HEAD>
    <META http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
    <META name="organization" content="ANSM : Agence Nationale de Sécurité du Médicament et des Produit de santé">
    <META name="description" content="Résumé des Caractéristiques du Produit">
    <META name="keywords" content="MUPHORAN, poudre et solution pour usage parentéral à diluer (perfusion), Médicament, Spécialité pharmaceutique, RCP, Résumé des Caractéristiques du Produit, Dénomination, Forme pharmaceutique, Indications, Contre-indications, Effets secondaires">
    <TITLE>Résumé des Caractéristiques du Produit</TITLE>
    <link rel="stylesheet" href="../style/spstyl01.css" type="text/css">
  </HEAD>
  <BODY>
<p class="AmmAnnexeTitre"><a name="RcpTitre">RÉSUMÉ DES CARACTÉRISTIQUES DU PRODUIT</a></p>
<p class="DateNotif">ANSM - Mis à jour le : 17/01/2014</p>
<p class="AmmAnnexeTitre1"><a name="RcpDenomination">1. DENOMINATION DU MEDICAMENT</a></p>
<p class=AmmDenomination>MUPHORAN, poudre et solution pour usage parentéral à diluer (perfusion)</p>
<p class="AmmAnnexeTitre1"><a name="RcpCompoQualitQuanti">2. COMPOSITION QUALITATIVE ET QUANTITATIVE</a></p>
<p class=AmmComposition>Fotémustine ................................................................................................................................ 208,00 mg</p>
<p class=AmmComposition align=center style='text-align:center'>Pour un flacon.</p>
<p class=AmmCorpsTexte>La solution reconstituée représente un volume de 4,16 ml, soit 200 mg de fotémustine dans 4 ml de solution.</p>
<p class=AmmCorpsTexte>Pour la liste complète des excipients, <a href="#Rcp_6_1_ListeExcipients_5"><span class=MsoPageNumber><span style='font-family:Arial'>voir rubrique 6.1</span></span></a>.</p>
<p class="AmmAnnexeTitre1"><a name="RcpFormePharm">3. FORME PHARMACEUTIQUE</a></p>
<p class=AmmCorpsTexte>Poudre et solution pour usage parentéral à diluer (perfusion).</p>
<p class="AmmAnnexeTitre1"><a name="RcpDonneesCliniques">4. DONNEES CLINIQUES</a></p>
<p class="AmmAnnexeTitre2"><a name="RcpIndicTherap">4.1. Indications thérapeutiques</a></p>
<p class=AmmCorpsTexte>Mélanome malin disséminé (y compris dans les localisations cérébrales).</p>
<p class=AmmCorpsTexte>Tumeurs cérébrales malignes primitives.</p>
<p class="AmmAnnexeTitre2"><a name="RcpPosoAdmin">4.2. Posologie et mode d'administration</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278909"></a><a name="Rcp_4_2_PosoAdmin_1"></a>Préparer la solution extemporanément.</p>
<p class=AmmCorpsTexte>Dissoudre le contenu du flacon de MUPHORAN avec l’ampoule de 4 ml de soluté alcoolique stérile puis après calcul de la dose à injecter, diluer la solution dans du soluté glucosé isotonique à 5 % pour l’administration en perfusion intraveineuse.</p>
<p class=AmmCorpsTexte><b>La solution ainsi préparée doit être utilisée à l’abri de la lumière : </b>par voie intraveineuse en perfusion d’une durée d’une heure.</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span><b><i>En monochimiothérapie, </i></b>le traitement comprend :</p>
<p class=AmmListePuces2 style='margin-left:35.45pt;text-indent:-21.25pt'><span style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>          </span></span>un traitement d’attaque : 3 administrations consécutives à une semaine d’intervalle, suivie d’un repos thérapeutique de 4 à 5 semaines ;</p>
<p class=AmmListePuces2 style='margin-left:35.45pt;text-indent:-21.25pt'><span style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>          </span></span>un traitement d’entretien : une administration toutes les 3 semaines.</p>
<p class=AmmCorpsTexte>La posologie habituelle est de 100 mg/m<sup>2</sup>.</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span><b><i>En polychimiothérapie, </i></b>la 3<sup>ème</sup> administration du traitement d’attaque est supprimée. La dose reste de</p>
<p class=AmmCorpsTexte>100 mg/m<sup>2</sup>.</p>
<p class=AmmCorpsTexte><b><u>Association avec la dacarbazine</u></b></p>
<p class=AmmCorpsTexte>De rares cas de toxicité pulmonaire (syndrome de détresse respiratoire aigüe de l’adulte) ont été observés lorsque la fotémustine a été associée simultanément, le même jour, à des doses élevées de dacarbazine.</p>
<p class=AmmCorpsTexte>L’administration <u>simultanée</u> doit être évitée (voir rubrique 4.5.).</p>
<p class=AmmCorpsTexte>L’administration doit être faite selon le schéma recommandé suivant :</p>
<p class=AmmCorpsTexte><i><u>Traitement d’attaque :</u></i></p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>fotémustine 100 mg/m²/jour aux jours 1 et 8,</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>dacarbazine 250 mg/m²/jour aux jours 15, 16, 17 et 18.</p>
<p class=AmmListePuces1 style='margin-top:6.0pt;margin-right:0cm;margin-bottom: 0cm;margin-left:0cm;margin-bottom:.0001pt;text-indent:0cm'>cinq semaines de repos thérapeutique, puis :</p>
<p class=AmmCorpsTexte style='margin-top:6.0pt;margin-right:0cm;margin-bottom: 0cm;margin-left:0cm;margin-bottom:.0001pt'><i><u>Traitement d’entretien</u> : </i>toutes les 3 semaines.</p>
<p class=AmmListePuces1 style='margin-top:6.0pt;text-align:justify'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>fotémustine 100 mg/m²/jour au jour 1,</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>dacarbazine 250 mg/m²/jour aux jours 2, 3, 4 et 5.</p>
<p class="AmmAnnexeTitre2"><a name="RcpContreIndic">4.3. Contre-indications</a></p>
<p class=AmmListePuces1 style='text-align:justify'><a name="_Toc142278910"></a><a name="Rcp_4_3_ContreIndic_2"></a><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span><span style='letter-spacing:.05pt'>Gr</span>o<span style='letter-spacing:.05pt'>ss</span>e<span style='letter-spacing:.05pt'>ss</span>e,<span style='letter-spacing:-.55pt'> </span>a<span style='letter-spacing:-.05pt'>ll</span><span style='letter-spacing:.1pt'>a</span><span style='letter-spacing:-.05pt'>i</span>te<span style='letter-spacing:.2pt'>m</span>ent,</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>H<span style='letter-spacing:-.2pt'>y</span><span style='letter-spacing:.1pt'>p</span>e<span style='letter-spacing:.05pt'>rs</span>en<span style='letter-spacing:.05pt'>s</span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.1pt'>b</span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>l</span><span style='letter-spacing:-.05pt'>i</span>té<span style='letter-spacing:-.6pt'> </span>à<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:.1pt'>l</span>a<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.1pt'>f</span>oté<span style='letter-spacing:.1pt'>m</span>u<span style='letter-spacing:.05pt'>s</span>t<span style='letter-spacing:-.05pt'>i</span>n<span style='letter-spacing:.1pt'>e</span> <span style='letter-spacing:.1pt'>o</span>u à<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:.05pt'>l</span><span style='letter-spacing:-.05pt'>’</span>un<span style='letter-spacing:-.05pt'> </span>des<span style='letter-spacing:-.1pt'> </span>e<span style='letter-spacing:.05pt'>xci</span>p<span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.1pt'>e</span>nt<span style='letter-spacing:.05pt'>s</span>.</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span><span style='letter-spacing:-.05pt'>E</span>n<span style='letter-spacing:.65pt'> </span>a<span style='letter-spacing:.05pt'>ss</span>o<span style='letter-spacing:.05pt'>c</span><span style='letter-spacing:-.05pt'>i</span>a<span style='letter-spacing:.1pt'>t</span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.1pt'>o</span>n<span style='letter-spacing:.25pt'> </span><span style='letter-spacing:.1pt'>a</span><span style='letter-spacing:-.05pt'>v</span>ec<span style='letter-spacing:.65pt'> </span><span style='letter-spacing:-.05pt'>l</span>e <span style='letter-spacing:.8pt'></span><span style='letter-spacing:.05pt'>v</span>a<span style='letter-spacing:.05pt'>cc</span><span style='letter-spacing:-.05pt'>i</span>n an<span style='letter-spacing:.1pt'>t</span><span style='letter-spacing:-.05pt'>i</span>a<span style='letter-spacing:.2pt'>m</span>a<span style='letter-spacing:.05pt'>r</span><span style='letter-spacing:-.05pt'>il</span>e <span style='letter-spacing:.05pt'>(</span><span style='letter-spacing:.1pt'>f</span><span style='letter-spacing:-.05pt'>i</span>è<span style='letter-spacing:-.05pt'>v</span><span style='letter-spacing:.05pt'>r</span>e <span style='letter-spacing:.5pt'></span><span style='letter-spacing:.2pt'>j</span>aune)<span style='letter-spacing:.55pt'> </span><span style='letter-spacing:.05pt'>(v</span>o<span style='letter-spacing:-.05pt'>i</span>r <span style='letter-spacing:.65pt'></span><span style='letter-spacing:.05pt'>r</span>ub<span style='letter-spacing:.15pt'>r</span><span style='letter-spacing:-.05pt'>i</span>q<span style='letter-spacing:.1pt'>u</span>e <span style='letter-spacing:.4pt'></span>4.5. Inte<span style='letter-spacing: .05pt'>r</span>a<span style='letter-spacing:.05pt'>c</span>t<span style='letter-spacing:.05pt'>i</span>ons a<span style='letter-spacing:.05pt'>v</span>ec d<span style='letter-spacing:.05pt'>’</span>aut<span style='letter-spacing: .05pt'>r</span><span style='letter-spacing:.1pt'>e</span>s <span style='letter-spacing:.2pt'>m</span>éd<span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>c</span><span style='letter-spacing:-.15pt'>a</span><span style='letter-spacing:.2pt'>m</span>ents<span style='letter-spacing:-.55pt'> </span>ou<span style='letter-spacing:-.15pt'> </span>aut<span style='letter-spacing:.15pt'>r</span>es<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:.1pt'>f</span>o<span style='letter-spacing:.05pt'>r</span><span style='letter-spacing:.2pt'>m</span><span style='letter-spacing:-.15pt'>e</span>s<span style='letter-spacing:-.25pt'> </span>d<span style='letter-spacing:-.05pt'>’i</span>n<span style='letter-spacing:.1pt'>t</span>e<span style='letter-spacing:.05pt'>r</span>a<span style='letter-spacing:.05pt'>c</span>t<span style='letter-spacing:.05pt'>i</span>on<span style='letter-spacing:.05pt'>s)</span>.</p>
<p class="AmmAnnexeTitre2"><a name="RcpMisesEnGarde">4.4. Mises en garde spéciales et précautions d'emploi</a></p>
<p class=AmmAnnexeTitre3><a name="_Toc142278913">Mises en garde spéciales</a></p>
<p class=AmmCorpsTexte><a name="Rcp_4_4_MisesEnGarde_3"></a>Eviter tout contact cutané, muqueux et toute absorption de la solution reconstituée. Le port d'un masque et de gants de protection est conseillé lors de la préparation de la solution. En cas de projection, laver abondamment à l'eau.</p>
<p class=AmmCorpsTexte>Le matériel contaminé doit être éliminé dans des conditions de sécurité.</p>
<p class=AmmCorpsTexte><u>Enfants</u> : <span style='letter-spacing:.1pt'>L</span><span style='letter-spacing:-.05pt'>’</span>u<span style='letter-spacing:.1pt'>t</span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>l</span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>s</span>a<span style='letter-spacing:.1pt'>t</span><span style='letter-spacing:-.05pt'>i</span>on<span style='letter-spacing:1.05pt'> </span>de<span style='letter-spacing:1.75pt'> </span>MUPHORAN<sup> <span style='letter-spacing:.35pt'></span></sup><span style='letter-spacing: .1pt'>n</span><span style='letter-spacing:-.05pt'>’</span>e<span style='letter-spacing:.05pt'>s</span>t<span style='letter-spacing:1.65pt'> </span>pas<span style='letter-spacing:1.65pt'> </span><span style='letter-spacing:.05pt'>r</span>e<span style='letter-spacing:.05pt'>c</span>o<span style='letter-spacing:.1pt'>mm</span>and<span style='letter-spacing:.1pt'>é</span>e <span style='letter-spacing:.05pt'>c</span>h<span style='letter-spacing:.1pt'>e</span>z<span style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>l</span>es<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:.1pt'>e</span>n<span style='letter-spacing:.1pt'>f</span>ants<span style='letter-spacing:-.3pt'> </span>et <span style='letter-spacing:-.05pt'>l</span>es<span style='letter-spacing:-.1pt'> </span>a<span style='letter-spacing:.1pt'>d</span>o<span style='letter-spacing:.05pt'>l</span>e<span style='letter-spacing:.05pt'>sc</span>ent<span style='letter-spacing:.05pt'>s</span>,<span style='letter-spacing:-.6pt'> </span><span style='letter-spacing:-.05pt'>l</span>e <span style='letter-spacing:.05pt'>r</span>ap<span style='letter-spacing:.1pt'>p</span>o<span style='letter-spacing:.05pt'>r</span>t<span style='letter-spacing:-.35pt'> </span>b<span style='letter-spacing:.1pt'>é</span>né<span style='letter-spacing:.1pt'>f</span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>c</span>e/<span style='letter-spacing:.05pt'>r</span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>s</span>que<span style='letter-spacing:-.6pt'> </span><span style='letter-spacing:.1pt'>n</span><span style='letter-spacing:-.05pt'>’</span><span style='letter-spacing:.3pt'>a</span><span style='letter-spacing:-.2pt'>y</span>ant<span style='letter-spacing:-.2pt'> </span>pas<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:.1pt'>é</span>té<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.1pt'>ét</span>ab<span style='letter-spacing:.05pt'>l</span>i<span style='letter-spacing:-.3pt'> </span><span style='letter-spacing:.1pt'>d</span>ans<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.05pt'>c</span>ette<span style='letter-spacing:-.1pt'> </span>p<span style='letter-spacing:.1pt'>o</span>p<span style='letter-spacing:.1pt'>u</span><span style='letter-spacing:-.05pt'>l</span>a<span style='letter-spacing:.1pt'>t</span><span style='letter-spacing:-.05pt'>i</span>on.</p>
<p class=AmmCorpsTexte><u>Sujets âgés</u><span style='letter-spacing:-.15pt'> </span>:<span style='letter-spacing:.15pt'> </span><span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:.1pt'> </span>to<span style='letter-spacing:.05pt'>x</span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>c</span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.1pt'>t</span>é<span style='letter-spacing:-.1pt'> </span>de<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:.1pt'> f</span>ot<span style='letter-spacing:-.15pt'>é</span><span style='letter-spacing:.2pt'>m</span>u<span style='letter-spacing:.05pt'>s</span>t<span style='letter-spacing:-.05pt'>i</span>ne<span style='letter-spacing:-.3pt'> </span>a<span style='letter-spacing:.15pt'> </span>été<span style='letter-spacing:.05pt'> c</span>o<span style='letter-spacing:.2pt'>m</span>pa<span style='letter-spacing:.05pt'>r</span>ée<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:.05pt'>c</span>h<span style='letter-spacing:.1pt'>e</span>z<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.1pt'>d</span>es<span style='letter-spacing:.15pt'> </span>pat<span style='letter-spacing:.05pt'>i</span>ents<span style='letter-spacing:-.05pt'> </span>de<span style='letter-spacing:.1pt'> </span>p<span style='letter-spacing:.05pt'>l</span><span style='letter-spacing:.1pt'>u</span>s<span style='letter-spacing:.2pt'> </span>de<span style='letter-spacing:.1pt'> </span>60<span style='letter-spacing:.1pt'> </span>ans<span style='letter-spacing:.15pt'> </span>et<span style='letter-spacing:.1pt'> </span>de <span style='letter-spacing:.2pt'>m</span>o<span style='letter-spacing:-.05pt'>i</span>ns<span style='letter-spacing:.05pt'> </span>de<span style='letter-spacing:.2pt'> </span>60 an<span style='letter-spacing:.05pt'>s</span>.<span style='letter-spacing:.4pt'> </span><span style='letter-spacing:.1pt'>L</span>a<span style='letter-spacing:.45pt'> </span><span style='letter-spacing:.05pt'>s</span>u<span style='letter-spacing:.05pt'>rv</span>en<span style='letter-spacing:.1pt'>u</span>e<span style='letter-spacing:.15pt'> </span><span style='letter-spacing:.1pt'>d</span>e<span style='letter-spacing:.45pt'> </span><span style='letter-spacing:.15pt'>t</span>h<span style='letter-spacing:.05pt'>r</span>o<span style='letter-spacing:.1pt'>m</span>bop<span style='letter-spacing:.1pt'>é</span>n<span style='letter-spacing:.05pt'>i</span>e<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:.05pt'>(</span>g<span style='letter-spacing:.05pt'>r</span>a<span style='letter-spacing:.1pt'>d</span>e<span style='letter-spacing:.25pt'> </span>I<span style='letter-spacing:.1pt'>I</span>I<span style='letter-spacing:.05pt'>)</span>,<span style='letter-spacing:.4pt'> </span><span style='letter-spacing:.05pt'>l</span>eu<span style='letter-spacing:.05pt'>c</span>o<span style='letter-spacing:.1pt'>p</span>én<span style='letter-spacing:.05pt'>i</span>e<span style='letter-spacing:.05pt'> (</span>g<span style='letter-spacing:.05pt'>r</span>a<span style='letter-spacing:.1pt'>d</span>e<span style='letter-spacing:.25pt'> </span>I<span style='letter-spacing:.1pt'>I</span>I)<span style='letter-spacing:.5pt'> </span>et<span style='letter-spacing:.6pt'> </span>to<span style='letter-spacing:.05pt'>x</span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>ci</span>té<span style='letter-spacing:.4pt'> </span><span style='letter-spacing:.1pt'>g</span>a<span style='letter-spacing:.05pt'>s</span>t<span style='letter-spacing:.05pt'>r</span>o<span style='letter-spacing:.2pt'>-</span><span style='letter-spacing:-.05pt'>i</span>nte<span style='letter-spacing:.05pt'>s</span><span style='letter-spacing:.1pt'>t</span><span style='letter-spacing:-.05pt'>i</span>n<span style='letter-spacing:.1pt'>a</span><span style='letter-spacing:-.05pt'>l</span>e<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:.05pt'>(</span>g<span style='letter-spacing:.05pt'>r</span>a<span style='letter-spacing:.1pt'>d</span>e<span style='letter-spacing:.25pt'> </span>III)<span style='letter-spacing:.65pt'> </span>éta<span style='letter-spacing:.05pt'>i</span>t <span style='letter-spacing:.05pt'>s</span><span style='letter-spacing:-.05pt'>i</span>gn<span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.1pt'>f</span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>c</span>a<span style='letter-spacing:.1pt'>t</span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>v</span>e<span style='letter-spacing:.2pt'>m</span>ent<span style='letter-spacing:-.8pt'> </span>p<span style='letter-spacing:-.05pt'>l</span>us<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.1pt'>f</span><span style='letter-spacing:.05pt'>r</span>éq<span style='letter-spacing:.1pt'>u</span>en<span style='letter-spacing:.05pt'>t</span>e<span style='letter-spacing:-.45pt'> </span><span style='letter-spacing:.05pt'>c</span><span style='letter-spacing:.1pt'>he</span>z<span style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>l</span>es pa<span style='letter-spacing:.1pt'>t</span><span style='letter-spacing:-.05pt'>i</span>ents<span style='letter-spacing:-.2pt'> </span>de<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.1pt'>p</span><span style='letter-spacing:.05pt'>l</span>us<span style='letter-spacing:-.15pt'> </span>de<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.1pt'>6</span>0<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.1pt'>a</span>n<span style='letter-spacing:.05pt'>s</span>.</p>
<p class=AmmCorpsTexte>Ce médicament est déconseillé avec les vaccins vivants atténués, la phénytoïne et la fosphénytoïne (<a href="#Rcp_4_5_Interactions_4"><span class=MsoPageNumber><span style='font-family:Arial;color:windowtext;text-decoration: none'>voir rubrique 4.5</span></span></a> <span style='color:black;letter-spacing: .1pt'>I</span><span style='color:black'>nte<span style='letter-spacing:.05pt'>r</span>a<span style='letter-spacing:.05pt'>c</span><span style='letter-spacing:.1pt'>t</span><span style='letter-spacing:-.05pt'>i</span>ons<span style='letter-spacing:-.45pt'> </span><span style='letter-spacing:.1pt'>a</span><span style='letter-spacing:-.05pt'>v</span>ec<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.1pt'>d</span><span style='letter-spacing:-.05pt'>’</span>a<span style='letter-spacing:.1pt'>u</span>t<span style='letter-spacing:.05pt'>r</span>es<span style='letter-spacing:-.3pt'> </span><span style='letter-spacing:.2pt'>m</span>éd<span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>c</span>a<span style='letter-spacing:.2pt'>m</span>ents<span style='letter-spacing:-.7pt'> </span>ou<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.1pt'>a</span>ut<span style='letter-spacing:.05pt'>r</span>es<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:.1pt'>f</span>o<span style='letter-spacing:-.1pt'>r</span><span style='letter-spacing:.2pt'>m</span>es<span style='letter-spacing:-.25pt'> </span>d<span style='letter-spacing:-.05pt'>’i</span>n<span style='letter-spacing:.1pt'>t</span>e<span style='letter-spacing:.05pt'>r</span>a<span style='letter-spacing:.05pt'>c</span>t<span style='letter-spacing:.05pt'>i</span>on<span style='letter-spacing:.05pt'>s).</span></span></p>
<p class=AmmCorpsTexte>Des cas de leucémies aiguës et de dysplasies de la moelle osseuse ont été rapportés chez les patients traités par nitrosourées<i>.</i></p>
<p class=AmmAnnexeTitre3>Précautions d'emploi</p>
<p class=AmmCorpsTexte>Il est conseillé de ne pas administrer le produit aux personnes ayant reçu une chimiothérapie depuis moins de 4 semaines (ou 6 semaines en cas de traitement antérieur par nitrosourée).</p>
<p class=AmmCorpsTexte>L'administration de MUPHORAN ne peut être envisagée que lorsque le nombre de plaquettes et/ou de granulocytes est acceptable, respectivement 100 000/mm<sup>3</sup> et 2 000/mm<sup>3</sup>.</p>
<p class=AmmCorpsTexte>Les numérations des formules sanguines seront effectuées avant chaque nouvelle administration et les doses ajustées en fonction du statut hématologique. Le schéma suivant pourra servir de guide.</p>
<table class=AmmCorpsTexteTable border=1 cellspacing=0 cellpadding=0
style='margin-left:3.5pt;border-collapse:collapse;border:none'>
<thead>
<tr>
<td width=224 style='width:168.15pt;border:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmTableauTitre1 align=center style='margin:0cm;margin-bottom:.0001pt; text-align:center'>Plaquettes (/mm<sup>3</sup>)</p>
</td>
<td width=224 style='width:168.15pt;border:solid windowtext 1.0pt;
border-left:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmTableauTitre1 align=center style='margin:0cm;margin-bottom:.0001pt; text-align:center'>Granulocytes (/mm<sup>3</sup>)</p>
</td>
<td width=231 style='width:173.25pt;border:solid windowtext 1.0pt;
border-left:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmTableauTitre1 align=center style='margin:0cm;margin-bottom:.0001pt; text-align:center'>Pourcentage de la dose à administrer</p>
</td>
</tr>
<tr>
<td width=224 valign=top style='width:168.15pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>&gt; 100 000</p>
</td>
<td width=224 valign=top style='width:168.15pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>&gt; 2 000</p>
</td>
<td width=231 valign=top style='width:173.25pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>100 %</p>
</td>
</tr>
<tr>
<td width=224 valign=top style='width:168.15pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>100 000&#8805; N&gt;80 000</p>
</td>
<td width=224 valign=top style='width:168.15pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>2 000&#8805; N&gt;1 500</p>
</td>
<td width=231 valign=top style='width:173.25pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>75 %</p>
</td>
</tr>
<tr>
<td width=224 valign=top style='width:168.15pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'> </p>
</td>
<td width=224 valign=top style='width:168.15pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>1 500&#8805; N&gt;1 000</p>
</td>
<td width=231 valign=top style='width:173.25pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>50 %</p>
</td>
</tr>
<tr>
<td width=224 valign=top style='width:168.15pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>N&#8804; 80 000</p>
</td>
<td width=224 valign=top style='width:168.15pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>&#8804; 1 000</p>
</td>
<td width=231 valign=top style='width:173.25pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=center style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:center'>Report du traitement</p>
</td>
</tr>
</thead>
</table>
<p class=AmmCorpsTexte style='margin-top:6.0pt'>Un délai de 8 semaines entre le début du traitement d'attaque et le début du traitement d'entretien est recommandé. Entre deux cycles d'entretien, un délai de 3 semaines est préconisé.</p>
<p class=AmmCorpsTexte>Le traitement d'entretien ne peut être envisagé que lorsque le nombre de plaquettes et/ou de granulocytes est acceptable, respectivement 100 000/mm<sup>3</sup> et 2 000/mm<sup>3</sup>.</p>
<p class=AmmCorpsTexte>Il est conseillé de pratiquer un contrôle des paramètres biologiques hépatiques au cours ou au décours du traitement d'attaque.</p>
<p class=AmmCorpsTexte>Ce médicament contient 80 % de volume d'éthanol (alcool), c'est-à-dire 1,3 g d'alcool pour 100 mg de fotémustine, ce qui équivaut à 32 ml de bière et à 13,3 ml de vin. Cette quantité peut être dangereuse chez les patients atteints d'alcoolisme. Elle doit également être prise en considération chez les patients à haut risque tels que ceux atteints de troubles hépatiques ou d'épilepsie.</p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'>Avant de démarrer la perfusion de MUPHORAN, vérifier qu<span class=AmmCorpsTexteCar1>e</span> le dispositif de perfusion intraveineux est correctement placé dans la veine afin d’éviter toute extravasation. En cas d’extravasation, arrêter la perfusion.</p>
<p class="AmmAnnexeTitre2"><a name="RcpInteractions">4.5. Interactions avec d'autres médicaments et autres formes d'interactions</a></p>
<p class=AmmCorpsTexte><a name="Rcp_4_5_Interactions_4"></a><b><u>INTERACTIONS COMMUNES A TOUS LES CYTOTOXIQUES</u></b></p>
<p class=AmmCorpsTexte>En raison de l'augmentation du risque thrombotique lors des affections tumorales, le recours à un traitement anticoagulant est fréquent. La grande variabilité de la coagulabilité au cours de ces affections, à laquelle s'ajoute l'éventualité d'une interaction entre les anticoagulants oraux et la chimiothérapie anticancéreuse, imposent, s'il est décidé de traiter le patient par anticoagulant oraux, d'augmenter la fréquence des contrôles de l'INR.</p>
<p class=AmmAnnexeTitre2Bis><a name="_Toc142278914">Associations contre-indiquées</a></p>
<p class=AmmCorpsTexte>(<a href="#Rcp_4_3_ContreIndic_2"><span class=MsoPageNumber><span style='font-family:Arial'>voir rubrique 4.3</span></span></a>)</p>
<p class=AmmCorpsTexte><b>+ Vaccin antiamarile (fièvre jaune)</b></p>
<p class=AmmCorpsTexte>Risque de maladie vaccinale généralisée mortelle.</p>
<p class=AmmAnnexeTitre2Bis style='page-break-after:auto'><a name="_Toc142278915">Associations déconseillées</a></p>
<p class=AmmCorpsTexte>(<a href="#Rcp_4_4_MisesEnGarde_3"><span class=MsoPageNumber><span style='font-family:Arial'>voir rubrique 4.4</span></span></a>)</p>
<p class=AmmCorpsTexte><b>+ Phénytoïne (et, par extrapolation, fosphénytoïne)</b></p>
<p class=AmmCorpsTexte>Risque de survenue de convulsions par diminution de l'absorption digestive de la seule phénytoïne par le cytotoxique, ou bien risque de majoration de la toxicité ou de perte d'efficacité du cytotoxique par augmentation de son métabolisme hépatique par la phénytoïne ou la fosphénytoïne.</p>
<p class=AmmCorpsTexte><b>+ Vaccins vivants atténués sauf antiamarile</b></p>
<p class=AmmCorpsTexte>Risque de maladie vaccinale généralisée éventuellement mortelle. Ce risque est majoré chez les sujets déjà immunodéprimés par la maladie sous-jacente.</p>
<p class=AmmCorpsTexte>Utiliser un vaccin inactivé lorsqu'il existe (poliomyélite).</p>
<p class=AmmAnnexeTitre2Bis style='page-break-after:auto'><a name="_Toc142278916">Associations à prendre en compte</a></p>
<p class=AmmCorpsTexte><b>+ Immunosuppresseurs</b></p>
<p class=AmmCorpsTexte>Immunodépression excessive avec risque de syndrome lymphoprolifératif.</p>
<p class=AmmCorpsTexte><b><u>INTERACTIONS SPECIFIQUES A LA FOTEMUSTINE</u></b></p>
<p class=AmmAnnexeTitre2Bis style='page-break-after:auto'><a name="_Toc142278917">Associations faisant l'objet de précautions d’emploi</a></p>
<p class=AmmCorpsTexte><b>+ Dacarbazine</b></p>
<p class=AmmCorpsTexte>Avec la dacarbazine à doses élevées: risque de toxicité pulmonaire (syndrome de détresse respiratoire aiguë de l'adulte).</p>
<p class=AmmCorpsTexte>Ne pas utiliser simultanément mais respecter un délai d'une semaine entre la dernière administration de fotémustine et le premier jour de la cure de dacarbazine (<a href="#Rcp_4_2_PosoAdmin_1"><span class=MsoPageNumber><span style='font-family:Arial'>voir rubrique 4.2</span></span></a>).</p>
<p class="AmmAnnexeTitre2"><a name="RcpGrossAllait">4.6. Grossesse et allaitement</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278919">MUPHORAN<sup><span style='letter-spacing:.6pt'> </span></sup>d<span style='letter-spacing:.1pt'>o</span><span style='letter-spacing:-.05pt'>i</span>t<span style='letter-spacing:.9pt'> </span><span style='letter-spacing:.1pt'>ê</span>t<span style='letter-spacing:.05pt'>r</span>e<span style='letter-spacing:.9pt'> </span><span style='letter-spacing:.1pt'>ad</span><span style='letter-spacing:.2pt'>m</span><span style='letter-spacing:-.05pt'>i</span>n<span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>s</span>t<span style='letter-spacing:.05pt'>r</span>é<span style='letter-spacing:.6pt'> </span>en<span style='letter-spacing:1.05pt'> </span>a<span style='letter-spacing:.05pt'>ss</span>o<span style='letter-spacing:.05pt'>c</span><span style='letter-spacing:-.05pt'>i</span>at<span style='letter-spacing:.05pt'>i</span>on<span style='letter-spacing:.65pt'> </span><span style='letter-spacing:.1pt'>a</span><span style='letter-spacing:.05pt'>v</span>ec<span style='letter-spacing:.9pt'> </span>une<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing:.05pt'>c</span>ont<span style='letter-spacing:.05pt'>r</span>a<span style='letter-spacing:.2pt'>c</span>ep<span style='letter-spacing:.1pt'>t</span><span style='letter-spacing:-.05pt'>i</span>on<span style='letter-spacing:.55pt'> </span>e<span style='letter-spacing:.1pt'>ff</span><span style='letter-spacing:-.05pt'>ic</span>a<span style='letter-spacing:.05pt'>c</span>e<span style='letter-spacing:.8pt'> </span><span style='letter-spacing:.05pt'>c</span>h<span style='letter-spacing:.1pt'>e</span>z<span style='letter-spacing:.9pt'> </span><span style='letter-spacing:-.05pt'>l</span>es<span style='letter-spacing:.95pt'> </span><span style='letter-spacing:.1pt'>f</span>e<span style='letter-spacing:.1pt'>m</span><span style='letter-spacing:.2pt'>m</span><span style='letter-spacing:-.15pt'>e</span>s<span style='letter-spacing:.8pt'> </span>en<span style='letter-spacing:.95pt'> </span><span style='letter-spacing:.1pt'>â</span>ge<span style='letter-spacing:.9pt'> </span><span style='letter-spacing:.1pt'>d</span>e p<span style='letter-spacing:.05pt'>r</span>o<span style='letter-spacing:.05pt'>cr</span>ée<span style='letter-spacing:.05pt'>r</span>.<span style='letter-spacing:-.45pt'> </span>Les ho<span style='letter-spacing:.1pt'>m</span><span style='letter-spacing:.2pt'>m</span>es<span style='letter-spacing:-.35pt'> </span>de<span style='letter-spacing:-.05pt'>v</span><span style='letter-spacing:.05pt'>r</span>ont<span style='letter-spacing:-.4pt'> </span><span style='letter-spacing:.1pt'>ê</span>t<span style='letter-spacing:.05pt'>r</span>e<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>i</span>n<span style='letter-spacing:.1pt'>f</span>o<span style='letter-spacing:-.1pt'>r</span><span style='letter-spacing:.2pt'>m</span>és<span style='letter-spacing:-.35pt'> </span>des<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:.2pt'>m</span>e<span style='letter-spacing:.05pt'>s</span>u<span style='letter-spacing:.05pt'>r</span>es<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:.05pt'>c</span>ont<span style='letter-spacing:.05pt'>r</span>a<span style='letter-spacing:.05pt'>c</span>ep<span style='letter-spacing:.1pt'>t</span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>v</span>es<span style='letter-spacing:-.6pt'> </span>ad<span style='letter-spacing:.1pt'>é</span>q<span style='letter-spacing:.1pt'>u</span>a<span style='letter-spacing:.1pt'>t</span>es<span style='letter-spacing:-.4pt'> </span>à<span style='letter-spacing:-.1pt'> </span>u<span style='letter-spacing:.1pt'>t</span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>l</span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>s</span>e<span style='letter-spacing:.05pt'>r</span>.</a></p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt; page-break-after:avoid'><b><u>Grossesse</u></b></p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt; page-break-after:avoid'>Il<span style='letter-spacing:.5pt'> </span>n<span style='letter-spacing:.05pt'>’</span>e<span style='letter-spacing:.05pt'>x</span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>s</span>te<span style='letter-spacing:.25pt'> </span><span style='letter-spacing:.1pt'>p</span>as<span style='letter-spacing:.5pt'> </span>de<span style='letter-spacing:.45pt'> </span><span style='letter-spacing:.1pt'>d</span>on<span style='letter-spacing:.1pt'>n</span>ée<span style='letter-spacing:.1pt'>s</span>,<span style='letter-spacing:.3pt'> </span>ou<span style='letter-spacing:.45pt'> </span>des<span style='letter-spacing:.5pt'> </span><span style='letter-spacing:.1pt'>d</span>on<span style='letter-spacing:.1pt'>n</span>ées<span style='letter-spacing:.3pt'> </span><span style='letter-spacing:.05pt'>l</span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.2pt'>m</span><span style='letter-spacing:-.05pt'>i</span>tée<span style='letter-spacing:.1pt'>s</span>,<span style='letter-spacing:.2pt'> </span><span style='letter-spacing:.05pt'>c</span>on<span style='letter-spacing:.05pt'>c</span>e<span style='letter-spacing:.05pt'>r</span>nant<span style='letter-spacing:.25pt'> </span><span style='letter-spacing:-.05pt'>l</span><span style='letter-spacing:.05pt'>’</span>ut<span style='letter-spacing:.05pt'>i</span><span style='letter-spacing:-.05pt'>li</span><span style='letter-spacing:.05pt'>s</span><span style='letter-spacing:.1pt'>a</span>t<span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.1pt'>o</span>n<span style='letter-spacing:.1pt'> </span>de<span style='letter-spacing:.55pt'> </span>MUPHORAN<sup> </sup><span style='letter-spacing:.05pt'>c</span>h<span style='letter-spacing:.1pt'>e</span>z<span style='letter-spacing:.3pt'> </span><span style='letter-spacing:.05pt'>l</span>es<span style='letter-spacing:.55pt'> </span><span style='letter-spacing:.1pt'>f</span>e<span style='letter-spacing:.1pt'>mm</span>es en<span style='letter-spacing:.05pt'>c</span>e<span style='letter-spacing:.05pt'>i</span>nte<span style='letter-spacing:.05pt'>s</span>.<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:.1pt'>L</span>es<span style='letter-spacing:.15pt'> </span>ét<span style='letter-spacing:.1pt'>u</span>des e<span style='letter-spacing:.1pt'>ff</span>e<span style='letter-spacing:.05pt'>c</span>tuées<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.05pt'>c</span>h<span style='letter-spacing:.1pt'>e</span>z<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.05pt'>l</span><span style='letter-spacing:.05pt'>’</span>an<span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.2pt'>m</span>al<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>s</span>ont<span style='letter-spacing:.15pt'> </span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.1pt'>n</span><span style='letter-spacing:.05pt'>s</span>uf<span style='letter-spacing:.1pt'>f</span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>s</span>antes<span style='letter-spacing:-.25pt'> </span>p<span style='letter-spacing:.1pt'>o</span>ur<span style='letter-spacing:.05pt'> </span>pe<span style='letter-spacing:.05pt'>r</span><span style='letter-spacing:.2pt'>m</span>ett<span style='letter-spacing:.05pt'>r</span>e<span style='letter-spacing:-.25pt'> </span>de<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:.05pt'>c</span>on<span style='letter-spacing:.05pt'>cl</span>u<span style='letter-spacing:.05pt'>r</span>e<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.05pt'>s</span>ur<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:.1pt'> </span>to<span style='letter-spacing:.05pt'>x</span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.2pt'>c</span><span style='letter-spacing:-.05pt'>i</span>té<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:.2pt'>s</span>ur<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.05pt'>la </span><span style='letter-spacing:.05pt'>r</span>ep<span style='letter-spacing:.05pt'>r</span>odu<span style='letter-spacing:.05pt'>c</span><span style='letter-spacing:.1pt'>t</span><span style='letter-spacing:-.05pt'>i</span>on<span style='letter-spacing:-.6pt'> </span><span style='letter-spacing:.15pt'>(</span><span style='letter-spacing:-.05pt'>v</span><span style='letter-spacing:.1pt'>o</span><span style='letter-spacing:-.05pt'>i</span>r<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>rubrique</span><span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:.1pt'>5</span>.3<span style='letter-spacing: .05pt'>)</span>.</p>
<p class=AmmCorpsTexte>MUPHORAN<sup><span style='letter-spacing:.75pt'> </span></sup>e<span style='letter-spacing:.05pt'>s</span>t<span style='letter-spacing:.2pt'> </span><span style='letter-spacing:.05pt'>c</span>ont<span style='letter-spacing:.05pt'>r</span>e<span style='letter-spacing:.2pt'>-</span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.1pt'>n</span>d<span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.1pt'>q</span>ué<span style='letter-spacing:-.35pt'> </span>p<span style='letter-spacing:.1pt'>e</span>nd<span style='letter-spacing:.1pt'>a</span>nt <span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:.2pt'> </span>g<span style='letter-spacing:.05pt'>r</span>o<span style='letter-spacing:.05pt'>ss</span>e<span style='letter-spacing:.05pt'>ss</span>e<span style='letter-spacing:-.15pt'> </span>et<span style='letter-spacing:.25pt'> </span><span style='letter-spacing:.05pt'>c</span>h<span style='letter-spacing:.1pt'>e</span>z<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.05pt'>l</span>es<span style='letter-spacing:.25pt'> </span><span style='letter-spacing:.1pt'>f</span>e<span style='letter-spacing:.1pt'>mm</span>es<span style='letter-spacing:.05pt'> </span>en<span style='letter-spacing:.2pt'> </span>âge<span style='letter-spacing:.15pt'> </span>de<span style='letter-spacing:.2pt'> </span>p<span style='letter-spacing:.05pt'>r</span>o<span style='letter-spacing:.05pt'>cr</span><span style='letter-spacing:.1pt'>é</span>er<span style='letter-spacing:.15pt'> </span>n<span style='letter-spacing:-.05pt'>’</span><span style='letter-spacing:.1pt'>u</span>t<span style='letter-spacing:.05pt'>i</span><span style='letter-spacing:-.05pt'>li</span><span style='letter-spacing:.05pt'>s</span>a<span style='letter-spacing:.1pt'>n</span>t<span style='letter-spacing:-.05pt'> </span><span style='letter-spacing:.1pt'>p</span>as<span style='letter-spacing:.25pt'> </span>de <span style='letter-spacing:.05pt'>c</span>ont<span style='letter-spacing:.05pt'>r</span>a<span style='letter-spacing:.05pt'>c</span>ep<span style='letter-spacing:.1pt'>t</span><span style='letter-spacing:-.05pt'>i</span>f<span style='letter-spacing:-.4pt'> </span><span style='letter-spacing:.05pt'>(</span><span style='letter-spacing:-.05pt'>v</span>o<span style='letter-spacing:-.05pt'>i</span>r<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>rubrique</span><span style='letter-spacing:-.2pt'> </span>4<span style='letter-spacing:.1pt'>.</span>3<span style='letter-spacing: .05pt'>)</span>.</p>
<p class=AmmCorpsTexte><b><u>Allaitement</u></b></p>
<p class=AmmCorpsTexte>L<span style='letter-spacing:-.05pt'>’</span>e<span style='letter-spacing:.05pt'>xcr</span>ét<span style='letter-spacing:.05pt'>i</span>on<span style='letter-spacing:-.4pt'> </span>de <span style='letter-spacing:-.05pt'>l</span>a<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.1pt'>f</span>oté<span style='letter-spacing:.2pt'>m</span>u<span style='letter-spacing:.05pt'>s</span>t<span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.1pt'>n</span>e<span style='letter-spacing:-.55pt'> </span>ou de<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.05pt'>s</span>es<span style='letter-spacing: -.1pt'> </span><span style='letter-spacing:.2pt'>m</span>étab<span style='letter-spacing:.1pt'>o</span><span style='letter-spacing:-.05pt'>li</span><span style='letter-spacing:.1pt'>t</span>es<span style='letter-spacing:-.45pt'> </span>d<span style='letter-spacing:.1pt'>a</span>ns<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.05pt'>l</span>e <span style='letter-spacing:-.05pt'>l</span><span style='letter-spacing:.1pt'>a</span><span style='letter-spacing:-.05pt'>i</span>t<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.2pt'>m</span>ate<span style='letter-spacing:.05pt'>r</span>nel<span style='letter-spacing:-.35pt'> </span>n<span style='letter-spacing:-.05pt'>’</span>e<span style='letter-spacing:.05pt'>s</span>t<span style='letter-spacing:-.1pt'> </span>pas <span style='letter-spacing:.05pt'>c</span>onn<span style='letter-spacing:.1pt'>u</span>e. Un<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>r</span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>s</span>q<span style='letter-spacing:.1pt'>u</span>e<span style='letter-spacing:-.3pt'> </span><span style='letter-spacing:.05pt'>c</span>h<span style='letter-spacing:.1pt'>e</span>z<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.05pt'>l</span>e<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.1pt'>n</span>o<span style='letter-spacing:.1pt'>u</span><span style='letter-spacing:-.05pt'>v</span>e<span style='letter-spacing:.1pt'>a</span>u<span style='letter-spacing:.2pt'>-</span>né/<span style='letter-spacing:.1pt'>n</span>ou<span style='letter-spacing:.05pt'>rr</span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>ss</span>on<span style='letter-spacing:-1.0pt'> </span><span style='letter-spacing:.1pt'>n</span>e<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.1pt'>p</span>eut<span style='letter-spacing:-.1pt'> </span>êt<span style='letter-spacing:.05pt'>r</span>e<span style='letter-spacing:-.05pt'> </span>e<span style='letter-spacing:.05pt'>xc</span><span style='letter-spacing:-.05pt'>l</span>u.</p>
<p class=AmmCorpsTexte>MUPHORAN<sup><span style='letter-spacing:.5pt'> </span></sup>e<span style='letter-spacing:.05pt'>s</span>t<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>c</span>ont<span style='letter-spacing:.05pt'>r</span>e<span style='letter-spacing:.05pt'>-i</span><span style='letter-spacing:.1pt'>n</span>d<span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.1pt'>q</span>ué<span style='letter-spacing:-.7pt'> </span><span style='letter-spacing:.1pt'>d</span>u<span style='letter-spacing:.05pt'>r</span>ant<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.1pt'>l</span><span style='letter-spacing:-.05pt'>’</span>a<span style='letter-spacing:.05pt'>l</span><span style='letter-spacing:-.05pt'>l</span><span style='letter-spacing:.1pt'>a</span><span style='letter-spacing:-.05pt'>i</span>te<span style='letter-spacing:.2pt'>m</span>ent<span style='letter-spacing:-.6pt'> </span><span style='letter-spacing:.05pt'>(v</span>o<span style='letter-spacing:-.05pt'>i</span>r<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>rubrique</span><span style='letter-spacing:-.35pt'> </span>4<span style='letter-spacing:.1pt'>.</span>3<span style='letter-spacing:.05pt'>)</span>.</p>
<p class=AmmCorpsTexte><b><u>Fertilité </u></b></p>
<p class=AmmCorpsTexte>Des<span style='letter-spacing:.2pt'> </span>étu<span style='letter-spacing:.1pt'>d</span>es<span style='letter-spacing:.1pt'> </span>de<span style='letter-spacing:.35pt'> </span>to<span style='letter-spacing:.05pt'>x</span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>c</span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.1pt'>t</span>é<span style='letter-spacing:.05pt'> </span><span style='letter-spacing:.1pt'>d</span>e<span style='letter-spacing:.2pt'> </span><span style='letter-spacing:.1pt'>d</span>o<span style='letter-spacing:.05pt'>s</span>es<span style='letter-spacing:.15pt'> </span><span style='letter-spacing:.05pt'>r</span>épét<span style='letter-spacing:.1pt'>é</span>es de<span style='letter-spacing:.2pt'> </span><span style='letter-spacing:.1pt'>f</span>oté<span style='letter-spacing:.2pt'>m</span>u<span style='letter-spacing:.05pt'>s</span>t<span style='letter-spacing:-.05pt'>i</span>ne<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>c</span>h<span style='letter-spacing:.1pt'>e</span>z<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.05pt'>’</span><span style='letter-spacing:.1pt'>a</span>n<span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.2pt'>m</span>al<span style='letter-spacing:-.05pt'> </span>ont<span style='letter-spacing:.2pt'> m</span>ont<span style='letter-spacing:.05pt'>r</span>é<span style='letter-spacing:-2.4pt'> </span>que<span style='letter-spacing:.3pt'> </span><span style='letter-spacing:-.05pt'>l</span>a<span style='letter-spacing:.35pt'> </span><span style='letter-spacing:.1pt'>f</span>e<span style='letter-spacing:.05pt'>r</span>t<span style='letter-spacing:-.05pt'>il</span><span style='letter-spacing:.05pt'>i</span>té <span style='letter-spacing:.1pt'>é</span>ta<span style='letter-spacing:.05pt'>i</span>t<span style='letter-spacing:.15pt'> </span>a<span style='letter-spacing:.1pt'>ff</span>e<span style='letter-spacing:.05pt'>c</span>tée <span style='letter-spacing:.05pt'>c</span>h<span style='letter-spacing:.1pt'>e</span>z<span style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>l</span>es<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:.2pt'>m</span>â<span style='letter-spacing:-.05pt'>l</span>es<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>(</span><span style='letter-spacing:-.05pt'>v</span><span style='letter-spacing:.1pt'>o</span><span style='letter-spacing:-.05pt'>i</span>r<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>rubrique</span><span style='letter-spacing:-.35pt'> </span>5.3<span style='letter-spacing:.05pt'>)</span>.</p>
<p class="AmmAnnexeTitre2"><a name="RcpConduite">4.7. Effets sur l'aptitude à conduire des véhicules et à utiliser des machines</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278920">Aucune étude concernant les effets sur l’aptitude à conduire des véhicules et à utiliser des machines n’a été menée. Cependant, il n’est pas recommandé de conduire immédiatement après une administration de MUPHORAN.</a></p>
<p class="AmmAnnexeTitre2"><a name="RcpEffetsIndesirables">4.8. Effets indésirables</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278921"><span style='letter-spacing: -.05pt'>A</span>u<span style='letter-spacing:.45pt'> </span><span style='letter-spacing:.05pt'>c</span>ou<span style='letter-spacing:.05pt'>r</span>s<span style='letter-spacing:.4pt'> </span>des<span style='letter-spacing:.5pt'> </span>e<span style='letter-spacing:.05pt'>ss</span>a<span style='letter-spacing:-.05pt'>i</span>s<span style='letter-spacing:.35pt'> </span><span style='letter-spacing:.05pt'>c</span><span style='letter-spacing:-.05pt'>li</span><span style='letter-spacing:.1pt'>n</span><span style='letter-spacing:-.05pt'>i</span>q<span style='letter-spacing:.1pt'>u</span>e<span style='letter-spacing:.05pt'>s</span>,<span style='letter-spacing:.15pt'> </span><span style='letter-spacing:-.05pt'>l</span>es<span style='letter-spacing:.5pt'> </span>p<span style='letter-spacing:.05pt'>r</span><span style='letter-spacing:-.05pt'>i</span>n<span style='letter-spacing:.05pt'>ci</span>paux<span style='letter-spacing:.2pt'> </span>e<span style='letter-spacing:.1pt'>ff</span>ets<span style='letter-spacing:.4pt'> </span><span style='letter-spacing:-.05pt'>i</span>ndé<span style='letter-spacing:.05pt'>s</span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>r</span>a<span style='letter-spacing:.1pt'>b</span><span style='letter-spacing:-.05pt'>l</span>es<span style='letter-spacing:.1pt'> </span>ont<span style='letter-spacing:.4pt'> </span>é<span style='letter-spacing:.1pt'>t</span>é<span style='letter-spacing:.4pt'> </span>d<span style='letter-spacing:.05pt'>’</span>o<span style='letter-spacing:.05pt'>r</span>d<span style='letter-spacing:.05pt'>r</span>e<span style='letter-spacing:.25pt'> </span><span style='letter-spacing:.1pt'>h</span>é<span style='letter-spacing:.2pt'>m</span>ato<span style='letter-spacing:-.05pt'>l</span>og<span style='letter-spacing:.05pt'>i</span>qu<span style='letter-spacing:.1pt'>e</span>,<span style='letter-spacing:-.15pt'> </span>po<span style='letter-spacing:.1pt'>u</span><span style='letter-spacing:-.05pt'>v</span><span style='letter-spacing:.1pt'>a</span>nt<span style='letter-spacing:.2pt'> </span>to<span style='letter-spacing:.1pt'>u</span><span style='letter-spacing:.05pt'>c</span>her <span style='letter-spacing:-.05pt'>l</span>es<span style='letter-spacing:.5pt'> </span>3<span style='letter-spacing:.5pt'> </span><span style='letter-spacing: -.05pt'>l</span><span style='letter-spacing:.05pt'>i</span>gn<span style='letter-spacing:.1pt'>é</span>e<span style='letter-spacing:.05pt'>s</span>.<span style='letter-spacing:.2pt'> </span>Cette<span style='letter-spacing:.3pt'> </span>to<span style='letter-spacing:.2pt'>x</span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>c</span><span style='letter-spacing:-.05pt'>i</span>té<span style='letter-spacing:.35pt'> </span>e<span style='letter-spacing:.05pt'>s</span>t<span style='letter-spacing:.4pt'> </span><span style='letter-spacing:.05pt'>r</span>eta<span style='letter-spacing:.05pt'>r</span>dée<span style='letter-spacing:.15pt'> </span>et<span style='letter-spacing:.45pt'> </span><span style='letter-spacing:.05pt'>c</span>a<span style='letter-spacing:.05pt'>r</span>a<span style='letter-spacing:.05pt'>c</span>té<span style='letter-spacing:.05pt'>r</span><span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>s</span><span style='letter-spacing:.1pt'>é</span>e par<span style='letter-spacing:.45pt'> </span>une<span style='letter-spacing: .4pt'> </span>a<span style='letter-spacing:.1pt'>n</span>é<span style='letter-spacing:.2pt'>m</span><span style='letter-spacing:-.05pt'>i</span>e<span style='letter-spacing:.2pt'> </span><span style='letter-spacing:.05pt'>(</span>14%)<span style='letter-spacing:.35pt'> </span>a<span style='letter-spacing:-.05pt'>i</span>n<span style='letter-spacing:.05pt'>s</span>i<span style='letter-spacing:.3pt'> </span>que<span style='letter-spacing:.4pt'> </span><span style='letter-spacing:.1pt'>p</span>ar<span style='letter-spacing:.45pt'> </span>une<span style='letter-spacing:.4pt'> </span>th<span style='letter-spacing:.05pt'>r</span>o<span style='letter-spacing:.2pt'>m</span>bop<span style='letter-spacing:.1pt'>é</span>n<span style='letter-spacing:.05pt'>i</span>e <span style='letter-spacing:.05pt'>(</span>40,3<span style='letter-spacing: .05pt'>%</span>)<span style='letter-spacing:.25pt'> </span><span style='letter-spacing:.1pt'>e</span>t<span style='letter-spacing:.45pt'> </span>par<span style='letter-spacing:.6pt'> </span>une<span style='letter-spacing:.55pt'> </span><span style='letter-spacing:.05pt'>l</span>eu<span style='letter-spacing:.05pt'>c</span>o<span style='letter-spacing:.1pt'>p</span>én<span style='letter-spacing:.05pt'>i</span>e<span style='letter-spacing:.05pt'> (</span>46<span style='letter-spacing:.1pt'>,</span>3<span style='letter-spacing:.05pt'>%</span>)<span style='letter-spacing:.25pt'> </span>d<span style='letter-spacing:.1pt'>o</span>nt<span style='letter-spacing:.5pt'> </span><span style='letter-spacing:-.05pt'>l</span>e<span style='letter-spacing:.6pt'> </span>na<span style='letter-spacing:.1pt'>d</span><span style='letter-spacing:-.05pt'>i</span>r<span style='letter-spacing:.55pt'> </span><span style='letter-spacing:.05pt'>s</span>u<span style='letter-spacing:.05pt'>r</span><span style='letter-spacing:-.05pt'>vi</span><span style='letter-spacing:.1pt'>e</span>nt<span style='letter-spacing:.2pt'> </span><span style='letter-spacing:.05pt'>r</span>e<span style='letter-spacing:.05pt'>s</span>pe<span style='letter-spacing:.05pt'>c</span><span style='letter-spacing:.1pt'>t</span><span style='letter-spacing:.05pt'>i</span><span style='letter-spacing:-.05pt'>v</span>e<span style='letter-spacing:.2pt'>m</span>ent<span style='letter-spacing:-.15pt'> </span>4<span style='letter-spacing:.65pt'> </span>à<span style='letter-spacing:.5pt'> </span>5<span style='letter-spacing:.5pt'> </span><span style='letter-spacing:.05pt'>s</span>e<span style='letter-spacing:.2pt'>m</span>a<span style='letter-spacing:-.05pt'>i</span>nes<span style='letter-spacing:.2pt'> </span><span style='letter-spacing:.1pt'>e</span>t<span style='letter-spacing:.45pt'> </span>5<span style='letter-spacing:.65pt'> </span>à<span style='letter-spacing:.5pt'> </span>6<span style='letter-spacing:.5pt'> </span><span style='letter-spacing:.05pt'>s</span>e<span style='letter-spacing:.2pt'>m</span>a<span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.1pt'>n</span>es ap<span style='letter-spacing:.05pt'>r</span>ès<span style='letter-spacing: -.2pt'> </span><span style='letter-spacing:-.05pt'>l</span>a p<span style='letter-spacing:.05pt'>r</span>e<span style='letter-spacing:.2pt'>m</span><span style='letter-spacing:-.05pt'>i</span>è<span style='letter-spacing:.05pt'>r</span>e<span style='letter-spacing:-.45pt'> </span>ad<span style='letter-spacing:.2pt'>m</span><span style='letter-spacing:-.05pt'>i</span>n<span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>s</span>t<span style='letter-spacing:.15pt'>r</span>at<span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.1pt'>o</span>n<span style='letter-spacing:-.65pt'> </span><span style='letter-spacing:.1pt'>a</span>u<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.05pt'>c</span>ou<span style='letter-spacing:.05pt'>r</span>s<span style='letter-spacing:-.2pt'> </span>du t<span style='letter-spacing:.05pt'>r</span>a<span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.1pt'>t</span>e<span style='letter-spacing:.2pt'>m</span>ent<span style='letter-spacing:-.5pt'> </span>d<span style='letter-spacing:.05pt'>’</span>att<span style='letter-spacing:.1pt'>a</span>que.<span style='letter-spacing:-.35pt'> </span>Des<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.1pt'>p</span>an<span style='letter-spacing:.2pt'>c</span><span style='letter-spacing:-.2pt'>y</span><span style='letter-spacing:.1pt'>t</span>op<span style='letter-spacing:.1pt'>é</span>n<span style='letter-spacing:-.05pt'>i</span>es<span style='letter-spacing:-.6pt'> </span><span style='letter-spacing:.1pt'>p</span>e<span style='letter-spacing:.1pt'>u</span><span style='letter-spacing:-.05pt'>v</span>e<span style='letter-spacing:.1pt'>n</span>t<span style='letter-spacing:-.4pt'> </span><span style='letter-spacing:.05pt'>s</span>u<span style='letter-spacing:.05pt'>rv</span>en<span style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:.05pt'>r</span>.</a></p>
<p class=AmmCorpsTexte>L’hématotoxicité et la toxicité gastro-intestinale sont plus sévères chez les sujets de plus de 60 ans.</p>
<p class=AmmCorpsTexte>Les effets indésirables rapportés sont listés ci-dessous par classe de système d’organe et par fréquence : très fréquent (&gt;1/10) ; fréquent (&gt;1/100, &lt;1/10) ; peu fréquent (&gt;1/1000, &lt;1/100) ; rare (&gt;1/10 000, &lt;1/1000) ; très rare (&lt;1/10 000) ; inconnu (ne peut être estimé d’après les données disponibles).</p>
<p class=AmmCorpsTexte><b><u>Affections hématologiques et du système lymphatique</u></b></p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'><i>Très fréquent :</i></p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>Thrombocytopénie, leucopénie (grade 3-4),</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>Anémie (grade 3-4).</p>
<p class=AmmCorpsTexte style='margin-top:6.0pt'><b><u>Affections du système nerveux</u></b></p>
<p class=AmmCorpsTexte style='margin-top:6.0pt;margin-right:0cm;margin-bottom: 0cm;margin-left:0cm;margin-bottom:.0001pt'><i>Peu fréquent :</i></p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>Troubles neurologiques transitoires et sans séquelle (troubles de la conscience, paresthésies, agueusie).</p>
<p class=AmmCorpsTexte style='margin-top:6.0pt'><b><u>Affections gastro-intestinales</u></b></p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'><i>Très fréquent :</i></p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>Nausées et vomissements modérés dans les 2 heures qui suivent l’injection.</p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'><i>Fréquent :</i></p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>Diarrhées, douleurs abdominales.</p>
<p class=AmmCorpsTexte style='margin-top:6.0pt'><b><u>Affections du rein et des voies urinaires</u></b></p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'><i>Peu fréquent :</i></p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>Elévation transitoire de l’urée.</p>
<p class=AmmCorpsTexte style='margin-top:6.0pt'><b><u>Affections de la peau et du tissu sous-cutané</u></b></p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'><i>Peu fréquent :</i></p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>Prurit.</p>
<p class=AmmCorpsTexte style='margin-top:6.0pt;page-break-after:avoid'><b><u>Troubles généraux et anomalies au site d'administration</u></b></p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt; page-break-after:avoid'><i>Fréquent :</i></p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>Episode fébrile,</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>Veinite au point d’injection.</p>
<p class=AmmCorpsTexte style='margin-top:6.0pt'><b><u>Affections hépato-biliaires</u></b></p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'><i>Très fréquent</i></p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>Elévations modérées, transitoires et réversibles des transaminases, des phosphatases alcalines et de la bilirubine.</p>
<p class=AmmCorpsTexte style='margin-bottom:0cm;margin-bottom:.0001pt'><i>Inconnu :</i></p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>Hépatite cytolytique, cholestatique ou mixte.</p>
<p class=AmmCorpsTexte style='margin-top:6.0pt'><b><u>Affections respiratoires, thoraciques et médiastinales </u></b></p>
<p class=AmmCorpsTexte>De rares cas de toxicité pulmonaire (syndrome de détresse respiratoire aigüe de l’adulte) ont été observés en association avec la dacarbazine (voir rubrique 4.5 Interactions médicamenteuses). Une toxicité pulmonaire à type de pneumopathie interstitielle a également été rapportée avec la fotémustine.</p>
<p class=AmmCorpsTexte><b><u>Tumeurs bénignes, malignes et non précisées (incluant kystes et polypes) </u></b></p>
<p class=AmmCorpsTexte>Les agents antinéoplasiques et particulièrement les agents alkylants ont été associés à un risque potentiel de syndrome myélodysplasique et de leucémie myéloïde aiguë. A doses cumulées élevées, de rares cas ont été rapportés avec MUPHORAN, en association ou non avec d’autres chimiothérapies, avec ou sans radiothérapie.</p>
<p class=AmmCorpsTexte><u><span lang=FR-BE>Déclaration des effets indésirables suspectés</span></u></p>
<p class=AmmCorpsTexte><span lang=FR-BE>La déclaration des effets indésirables suspectés après autorisation du médicament est importante. Elle permet une surveillance continue du rapport bénéfice/risque du médicament. </span>Les professionnels de santé déclarent tout effet indésirable suspecté via le système national de déclaration : Agence nationale de sécurité du médicament et des produits de santé (Ansm) et réseau des Centres Régionaux de Pharmacovigilance - Site internet: <a href="http://www.ansm.sante.fr/"><span lang=PT>www.ansm.sante.fr</span></a> </p>
<p class="AmmAnnexeTitre2"><a name="RcpSurdosage">4.9. Surdosage</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278922">Surveillance hématologique accrue. Il n’y a pas d’antidote connu.</a></p>
<p class="AmmAnnexeTitre1"><a name="RcpPropPharmacologie">5. PROPRIETES PHARMACOLOGIQUES</a></p>
<p class="AmmAnnexeTitre2"><a name="RcpPropPharmacodynamie">5.1. Propriétés pharmacodynamiques</a></p>
<p class=AmmCorpsTexteGras><a name="_Toc142278924"></a>Groupe pharmacothérapeutique : Agents anti-néoplasique, agents alkylants, nitrosourées code ATC : L01AD05</p>
<p class=AmmCorpsTexte>La fotémustine est un agent anti-cancéreux cytostatique de la famille des nitrosourées, à effet alkylant et carbamylant, à spectre d’activité anti-tumorale expérimentale large.</p>
<p class=AmmCorpsTexte>Sa formule chimique comporte un bioisostère de l’alanine (acide amino-1-éthylphosphonique) qui facilite la pénétration cellulaire et le franchissement de la barrière hématoencéphalique.</p>
<p class="AmmAnnexeTitre2"><a name="RcpPropPharmacocinetique">5.2. Propriétés pharmacocinétiques</a></p>
<p class=AmmCorpsTexte>Chez l’homme, après perfusion intraveineuse, la cinétique d’élimination plasmatique est mono ou bi-exponentielle avec une demi-vie terminale courte.</p>
<p class=AmmCorpsTexte>La molécule est pratiquement totalement métabolisée.</p>
<p class=AmmCorpsTexte>La fixation aux protéines plasmatiques est faible (25 à 30 %). La fotémustine franchit la barrière hémato-méningée.</p>
<p class="AmmAnnexeTitre2"><a name="RcpSecuritePreclinique">5.3. Données de sécurité préclinique</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278926">Il n’y a pas d’études menées sur la reproduction avec la fotémustine. Les autres molécules de la classe des nitrosourées se sont avérées être tératogènes et embryotoxiques lors d’études chez l’animal.</a></p>
<p class=AmmCorpsTexte>Des études de toxicité de doses répétées de fotémustine chez le rat et le chien ont montré que la fertilité était affectée chez les mâles (azoospermie et atrophie testiculaire chez le rat).</p>
<p class=AmmCorpsTexte>La fotémustine présente un caractère mutagène (tests de mutation sur Salmonella typhimurium et E. coli), ainsi qu’un caractère clastogène (test du micronucleus chez la souris, test in vitro sur lymphocyte humain).</p>
<p class=AmmCorpsTexte>La fotémustine présente <i>in vitro </i>un effet transformant et initiateur sur deux lignées étudiées (tests sur cellules embryonnaires de hamster syrien et sur cellules BALB/3T3). La fotémustine possède un potentiel cancérogène lié à son potentiel génotoxique et se comporte comme un initiateur.</p>
<p class="AmmAnnexeTitre1"><a name="RcpDonneesPharmaceutiques">6. DONNEES PHARMACEUTIQUES</a></p>
<p class="AmmAnnexeTitre2"><a name="RcpListeExcipients">6.1. Liste des excipients</a></p>
<p class=AmmCorpsTexte><a name="Rcp_6_1_ListeExcipients_5"></a><u>Solvant</u>: éthanol à 80 % v/v (soit éthanol à 95 % v/v et eau pour préparations injectables).</p>
<p class="AmmAnnexeTitre2"><a name="RcpIncompatibilites">6.2. Incompatibilités</a></p>
<p class=AmmCorpsTexte>Sans objet.</p>
<p class="AmmAnnexeTitre2"><a name="RcpDureeConservation">6.3. Durée de conservation</a></p>
<p class=AmmCorpsTexte>2 ans à l'abri de la lumière.</p>
<p class="AmmAnnexeTitre2"><a name="RcpPrecConservation">6.4. Précautions particulières de conservation</a></p>
<p class=AmmCorpsTexte>A conserver au réfrigérateur entre 2°C et 8°C.</p>
<p class=AmmCorpsTexte>La solution reconstituée doit être utilisée immédiatement.</p>
<p class="AmmAnnexeTitre2"><a name="RcpEmballage">6.5. Nature et contenu de l'emballage extérieur</a></p>
<p class=AmmCorpsTexte>Flacon en verre brun et ampoule de solvant en verre (4 ml).</p>
<p class="AmmAnnexeTitre2"><a name="RcpPrecEmpl">6.6. Précautions particulières d’élimination et de manipulation</a></p>
<p class=AmmCorpsTexte>Pas d'exigences particulières.</p>
<p class="AmmAnnexeTitre1"><a name="RcpTitulaireAmm">7. TITULAIRE DE L’AUTORISATION DE MISE SUR LE MARCHE</a></p>
<p class=AmmTitulaireNom>LES LABORATOIRES SERVIER</p>
<p class=AmmTitulaireAdresse>50, rue Carnot</p>
<p class=AmmTitulaireAdresse>92284 SURESNES Cedex</p>
<p class="AmmAnnexeTitre1"><a name="RcpPresentation">8. NUMERO(S) D’AUTORISATION DE MISE SUR LE MARCHE</a></p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>331 870-2: 208 mg de poudre en flacon (verre brun) + 4 ml de solvant en ampoule (verre).</p>
<p class="AmmAnnexeTitre1"><a name="RcpPremiereAutorisation">9. DATE DE PREMIERE AUTORISATION/DE RENOUVELLEMENT DE L’AUTORISATION</a></p>
<p class=AmmCorpsTexte>[à compléter par le titulaire]</p>
<p class="AmmAnnexeTitre1"><a name="RcpDateRevision">10. DATE DE MISE A JOUR DU TEXTE</a></p>
<p class=AmmCorpsTexte>[à compléter par le titulaire]</p>
<p class="AmmAnnexeTitre1"><a name="RcpDosimetrie">11. DOSIMETRIE</a></p>
<p class=AmmCorpsTexte>Sans objet.</p>
<p class="AmmAnnexeTitre1"><a name="RcpInstPrepRadioph">12. INSTRUCTIONS POUR LA PREPARATION DES RADIOPHARMACEUTIQUES</a></p>
<p class=AmmCorpsTexte>Sans objet.</p>
<div style='border:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0cm 0cm 0cm'>
<p class="AmmAnnexeTitre"><a name="RcpCondPrescription">CONDITIONS DE PRESCRIPTION ET DE DELIVRANCE</a></p>
</div>
<p class=AmmCorpsTexte>Liste I.</p>
<p class=AmmCorpsTexte>Médicament soumis à prescription hospitalière. Prescription réservée aux spécialistes en oncologie ou en hématologie ou aux médecins compétents en cancérologie.</p>
<p class=AmmCorpsTexte>Médicament nécessitant une surveillance particulière pendant le traitement.</p>
<p class=AmmAnnexeTitre><a name="_Toc142278940"></a></p>
<b><span style='font-size:12.0pt;font-family:Arial;color:#0B3D92;text-transform:
uppercase'><br clear=all>
</span></b>
</BODY>
</HTML>
